Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

E. Anders Kolb, Richard Gorlick, C. Patrick Reynolds, Min H. Kang, Hernan Carol, Richard Lock, Stephen T. Keir, John M. Maris, Catherine A. Billups, Christopher Desjardins, Raushan T. Kurmasheva, Peter J. Houghton, Malcolm A. Smith

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

Background: Antimitotic agents are essential components for curative therapy of pediatric acute leukemias and many solid tumors. Eribulin is a novel agent that differs from both Vinca alkaloids and taxanes in its mode of binding to tubulin polymers. Procedures: Eribulin was tested against the PPTP in vitro cell line panel at concentrations from 0.1nM to 1.0μM and against the PPTP in vivo xenograft panels at a dose of 1mg/kg (solid tumors) or 1.5mg/kg (ALL models) using a q4dx3 schedule repeated at Day 21. Results: In vitro eribulin demonstrated cytotoxic activity, with a median relative IC50 value of 0.27nM, (range <0.1-14.8nM). Eribulin was well tolerated in vivo, and all 43 xenograft models were considered evaluable for efficacy. Eribulin induced significant differences in event-free survival (EFS) distribution compared to control in 29 of 35 (83%) of the solid tumors and in 8 of 8 (100%) of the ALL xenografts. Objective responses were observed in 18 of 35 (51%) solid tumor xenografts. Complete responses (CR) or maintained CR were observed in panels of Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, glioblastoma, and osteosarcoma xenografts. All eight ALL xenografts achieved CR or MCR. Conclusions: The high level of activity observed for eribulin against the PPTP preclinical models makes this an interesting agent to consider for pediatric evaluation. The activity pattern observed for eribulin in the solid tumor panels is equal or superior to that observed previously for vincristine.

Original languageEnglish (US)
Pages (from-to)1325-1332
Number of pages8
JournalPediatric Blood and Cancer
Volume60
Issue number8
DOIs
StatePublished - Aug 2013

Fingerprint

eribulin
Tubulin
Heterografts
Pediatrics
Neoplasms
Vinca Alkaloids
Antimitotic Agents
Taxoids
Ewing's Sarcoma
Wilms Tumor
Rhabdomyosarcoma
Vincristine
Osteosarcoma
Glioblastoma
Inhibitory Concentration 50
Disease-Free Survival
Appointments and Schedules

Keywords

  • Developmental therapeutics
  • PI3K inhibitor
  • Preclinical testing

ASJC Scopus subject areas

  • Oncology
  • Pediatrics, Perinatology, and Child Health
  • Hematology

Cite this

Kolb, E. A., Gorlick, R., Reynolds, C. P., Kang, M. H., Carol, H., Lock, R., ... Smith, M. A. (2013). Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. Pediatric Blood and Cancer, 60(8), 1325-1332. https://doi.org/10.1002/pbc.24517

Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. / Kolb, E. Anders; Gorlick, Richard; Reynolds, C. Patrick; Kang, Min H.; Carol, Hernan; Lock, Richard; Keir, Stephen T.; Maris, John M.; Billups, Catherine A.; Desjardins, Christopher; Kurmasheva, Raushan T.; Houghton, Peter J.; Smith, Malcolm A.

In: Pediatric Blood and Cancer, Vol. 60, No. 8, 08.2013, p. 1325-1332.

Research output: Contribution to journalArticle

Kolb, EA, Gorlick, R, Reynolds, CP, Kang, MH, Carol, H, Lock, R, Keir, ST, Maris, JM, Billups, CA, Desjardins, C, Kurmasheva, RT, Houghton, PJ & Smith, MA 2013, 'Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program', Pediatric Blood and Cancer, vol. 60, no. 8, pp. 1325-1332. https://doi.org/10.1002/pbc.24517
Kolb, E. Anders ; Gorlick, Richard ; Reynolds, C. Patrick ; Kang, Min H. ; Carol, Hernan ; Lock, Richard ; Keir, Stephen T. ; Maris, John M. ; Billups, Catherine A. ; Desjardins, Christopher ; Kurmasheva, Raushan T. ; Houghton, Peter J. ; Smith, Malcolm A. / Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program. In: Pediatric Blood and Cancer. 2013 ; Vol. 60, No. 8. pp. 1325-1332.
@article{b564e92d9d2b4028ad747242d1fad212,
title = "Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program",
abstract = "Background: Antimitotic agents are essential components for curative therapy of pediatric acute leukemias and many solid tumors. Eribulin is a novel agent that differs from both Vinca alkaloids and taxanes in its mode of binding to tubulin polymers. Procedures: Eribulin was tested against the PPTP in vitro cell line panel at concentrations from 0.1nM to 1.0μM and against the PPTP in vivo xenograft panels at a dose of 1mg/kg (solid tumors) or 1.5mg/kg (ALL models) using a q4dx3 schedule repeated at Day 21. Results: In vitro eribulin demonstrated cytotoxic activity, with a median relative IC50 value of 0.27nM, (range <0.1-14.8nM). Eribulin was well tolerated in vivo, and all 43 xenograft models were considered evaluable for efficacy. Eribulin induced significant differences in event-free survival (EFS) distribution compared to control in 29 of 35 (83{\%}) of the solid tumors and in 8 of 8 (100{\%}) of the ALL xenografts. Objective responses were observed in 18 of 35 (51{\%}) solid tumor xenografts. Complete responses (CR) or maintained CR were observed in panels of Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, glioblastoma, and osteosarcoma xenografts. All eight ALL xenografts achieved CR or MCR. Conclusions: The high level of activity observed for eribulin against the PPTP preclinical models makes this an interesting agent to consider for pediatric evaluation. The activity pattern observed for eribulin in the solid tumor panels is equal or superior to that observed previously for vincristine.",
keywords = "Developmental therapeutics, PI3K inhibitor, Preclinical testing",
author = "Kolb, {E. Anders} and Richard Gorlick and Reynolds, {C. Patrick} and Kang, {Min H.} and Hernan Carol and Richard Lock and Keir, {Stephen T.} and Maris, {John M.} and Billups, {Catherine A.} and Christopher Desjardins and Kurmasheva, {Raushan T.} and Houghton, {Peter J.} and Smith, {Malcolm A.}",
year = "2013",
month = "8",
doi = "10.1002/pbc.24517",
language = "English (US)",
volume = "60",
pages = "1325--1332",
journal = "Pediatric Blood and Cancer",
issn = "1545-5009",
publisher = "Wiley-Liss Inc.",
number = "8",

}

TY - JOUR

T1 - Initial testing (stage 1) of eribulin, a novel tubulin binding agent, by the pediatric preclinical testing program

AU - Kolb, E. Anders

AU - Gorlick, Richard

AU - Reynolds, C. Patrick

AU - Kang, Min H.

AU - Carol, Hernan

AU - Lock, Richard

AU - Keir, Stephen T.

AU - Maris, John M.

AU - Billups, Catherine A.

AU - Desjardins, Christopher

AU - Kurmasheva, Raushan T.

AU - Houghton, Peter J.

AU - Smith, Malcolm A.

PY - 2013/8

Y1 - 2013/8

N2 - Background: Antimitotic agents are essential components for curative therapy of pediatric acute leukemias and many solid tumors. Eribulin is a novel agent that differs from both Vinca alkaloids and taxanes in its mode of binding to tubulin polymers. Procedures: Eribulin was tested against the PPTP in vitro cell line panel at concentrations from 0.1nM to 1.0μM and against the PPTP in vivo xenograft panels at a dose of 1mg/kg (solid tumors) or 1.5mg/kg (ALL models) using a q4dx3 schedule repeated at Day 21. Results: In vitro eribulin demonstrated cytotoxic activity, with a median relative IC50 value of 0.27nM, (range <0.1-14.8nM). Eribulin was well tolerated in vivo, and all 43 xenograft models were considered evaluable for efficacy. Eribulin induced significant differences in event-free survival (EFS) distribution compared to control in 29 of 35 (83%) of the solid tumors and in 8 of 8 (100%) of the ALL xenografts. Objective responses were observed in 18 of 35 (51%) solid tumor xenografts. Complete responses (CR) or maintained CR were observed in panels of Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, glioblastoma, and osteosarcoma xenografts. All eight ALL xenografts achieved CR or MCR. Conclusions: The high level of activity observed for eribulin against the PPTP preclinical models makes this an interesting agent to consider for pediatric evaluation. The activity pattern observed for eribulin in the solid tumor panels is equal or superior to that observed previously for vincristine.

AB - Background: Antimitotic agents are essential components for curative therapy of pediatric acute leukemias and many solid tumors. Eribulin is a novel agent that differs from both Vinca alkaloids and taxanes in its mode of binding to tubulin polymers. Procedures: Eribulin was tested against the PPTP in vitro cell line panel at concentrations from 0.1nM to 1.0μM and against the PPTP in vivo xenograft panels at a dose of 1mg/kg (solid tumors) or 1.5mg/kg (ALL models) using a q4dx3 schedule repeated at Day 21. Results: In vitro eribulin demonstrated cytotoxic activity, with a median relative IC50 value of 0.27nM, (range <0.1-14.8nM). Eribulin was well tolerated in vivo, and all 43 xenograft models were considered evaluable for efficacy. Eribulin induced significant differences in event-free survival (EFS) distribution compared to control in 29 of 35 (83%) of the solid tumors and in 8 of 8 (100%) of the ALL xenografts. Objective responses were observed in 18 of 35 (51%) solid tumor xenografts. Complete responses (CR) or maintained CR were observed in panels of Wilms tumor, Ewing sarcoma, rhabdomyosarcoma, glioblastoma, and osteosarcoma xenografts. All eight ALL xenografts achieved CR or MCR. Conclusions: The high level of activity observed for eribulin against the PPTP preclinical models makes this an interesting agent to consider for pediatric evaluation. The activity pattern observed for eribulin in the solid tumor panels is equal or superior to that observed previously for vincristine.

KW - Developmental therapeutics

KW - PI3K inhibitor

KW - Preclinical testing

UR - http://www.scopus.com/inward/record.url?scp=84879198533&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879198533&partnerID=8YFLogxK

U2 - 10.1002/pbc.24517

DO - 10.1002/pbc.24517

M3 - Article

C2 - 23553917

AN - SCOPUS:84879198533

VL - 60

SP - 1325

EP - 1332

JO - Pediatric Blood and Cancer

JF - Pediatric Blood and Cancer

SN - 1545-5009

IS - 8

ER -